Top 10 pharmaceutical companies by revenues in 2026 | Official Figures | iPharmaCenter
- Badari Andukuri
- 7 days ago
- 7 min read
Updated: 6 days ago
Sl No | Brand | Q1 | H1 | 9M | Total |
1 | Johnson and Johnson | $24.1 | $49.4 | ||
2 | Roche | $18.8 | $45.5 | ||
3 | Eli Lilly | $19.8 | $42.8 | ||
4 | AbbVie | $15.0 | $32.0 | ||
5 | AstraZeneca | $15.3 | $30.7 | ||
6 | Pfizer | $14.4 | $29.5 | ||
7 | Merck | $14.3 | $29.1 | ||
8 | Novartis | $13.1 | $27.5 | ||
9 | Novo Nordisk | $15.2 | $27.0 | ||
10 | Sanofi | $12.4 | $25.3 |
The first quarter of 2026 confirmed that GLP-1 drugs are still rewriting the global pharmaceutical revenue rankings. Eli Lilly posted $19.8 billion revenues, the fastest rate among the top 10 companies, driven entirely by Mounjaro and Zepbound demand. Johnson and Johnson retained the top position at $24.1 billion, while Novo Nordisk climbed from 9th in 2025 to 5th in Q1 2026 on the strength of its expanding GLP-1 portfolio.
JOHNSON AND JOHNSON
Q1 REVENUES:
In the first quarter of 2026, the company reported total sales of $24.1 billion, reflecting a 9.9% increase. Revenue from Innovative Medicines reached $15.4 billion.
Global operational sales in the Innovative Medicines segment rose by 7.4%. This growth was mainly supported by strong performance from Darzalex, Carvykti, Erleada, and Rybrevant/Lazcluze in oncology, Tremfya in immunology, and Spravato in neuroscience.
Also read: Foundayo (orforglipron) Wins FDA Approval as First Anytime GLP‑1 Tablet for Weight Loss
Q2 REVENUES:
Johnson & Johnson reported solid financial performance for the second quarter of 2026, with total sales rising 6.6% year-over-year to reach $25.3 billion. The company’s Innovative Medicine segment generated $16.4 billion in revenue during the quarter, marking a 7.8% increase compared to the same period last year.
Among its top-performing products, Darzalex remained a major contributor, delivering $4.2 billion in Q2 sales and bringing its first-half total to $8.2 billion. The multiple myeloma treatment continues to demonstrate robust uptake globally.
Meanwhile, Tremfya also showed strong momentum, with revenues reaching $3.7 billion for the first half of 2026, supported by expanding use in immunological indications.
ROCHE
Q1 REVENUES:
Roche reported group sales growth of 6% at constant exchange rates (CER), while sales declined 5% in Swiss francs (CHF) and increased 9% in U.S. dollars. The Pharmaceuticals Division posted a 7% rise in sales at CER, with a 4% decline in CHF terms and a 10% increase in USD.
This performance was driven by sustained demand for therapies targeting serious conditions, particularly Xolair (chronic hives, food allergies), Phesgo (breast cancer), Hemlibra (haemophilia A), Vabysmo (severe eye diseases), and Ocrevus (multiple sclerosis).
Q2 REVENUES:
Roche delivered solid underlying growth in the first half of 2026, with group sales up 6% at constant exchange rates and down 2% in Swiss francs as the strong currency weighed on reported figures.
First‑half revenues came to approximately $45.5 billion (CHF 36.7 billion).
In the Pharmaceuticals Division, sales increased 6% at constant exchange rates, declined 1% in Swiss francs and rose 8% in U.S. dollars. Ocrevus generated $4.3 billion (CHF 3.47 billion) in revenue in the period, Vabysmo $2.5 billion (CHF 2.05 billion) and Tecentriq $2.1 billion (CHF 1.7 billion).
ELI LILLY
Q1 REVENUES:
Revenue in the first quarter of 2026 rose by 56% to $19.8 billion, largely driven by higher volumes, with some offset from lower realized prices for Mounjaro and Zepbound.
Combined revenue from Ebglyss, Inluriyo, Jaypirca, Kisunla, Mounjaro, Omvoh, and Zepbound reached $13.4 billion, supported mainly by strong demand for Mounjaro and Zepbound.
Additionally, key products across the immunology, oncology, and neuroscience segments recorded a 160% increase in revenue.
Q2 REVENUES/H1 REVENUES:
Eli Lilly reported second-quarter 2026 revenue of $23.0 billion, marking a 48 percent jump compared to the same period last year. The company said the surge was largely fueled by strong demand for its diabetes and weight-loss medicines, Mounjaro and Zepbound.
In the United States, Lilly’s revenue climbed 33 percent to $14.4 billion. This growth was driven by a 37 percent increase in prescription volume, though it was slightly tempered by a 3 percent decline in average realized prices.
For the first half of 2026, Lilly’s total revenue reached $42.8 billion, reflecting continued strength across its metabolic disease portfolio.
Mounjaro and Zepbound Lead Product Portfolio
Mounjaro continued to dominate Lilly’s lineup, generating $18.6 billion in revenue during the first six months of 2026. Zepbound, the company’s weight-management therapy, added another $9.0 billion in the same period, reflecting rapid uptake in both domestic and international markets.
ABBVIE
Q1 REVENUES
AbbVie reported first-quarter worldwide net revenues of $15.0 billion, representing growth of 12.4% on a reported basis and 10.3% on an operational basis.
Skyrizi generated global net revenues of $4.5 billion, rising 30.9% as reported and 29.2% operationally.
Rinvoq recorded global net revenues of $2.1 billion, reflecting an increase of 23.3% on a reported basis and 20.2% on an operational basis.
Q2 REVENUES/ H1 REVENUES
AbbVie reported second-quarter 2026 net revenues of 16.99 billion dollars, up 10.2 percent compared to the same period last year, driven by robust performance from its immunology portfolio. For the first half of 2026, the company achieved total net revenues of approximately $32 billion.
Skyrizi generated $5.5 billion in second-quarter 2026 revenues, making it AbbVie's leading product with first-half sales approaching $10 billion. Rinvoq followed as the second-best performer, posting $2.5 billion dollars in Q2 revenues and 4.6 billion dollars for the first six months of 2026.
ASTRAZENECA
Q1 REVENUES
Total revenue reached $15.3 billion, marking an 8% increase to $15,288 million, supported by double-digit growth in the oncology and rare disease segments.
Key contributors to this performance included Tagrisso, Imfinzi, and Farxiga.
Q2 REVENUES
AstraZeneca reported total revenue of $30.7 billion for the first half of the year, marking a 6% increase. Growth was driven by strong double-digit performance in Oncology and Rare Diseases, which helped offset pressures from Farxiga’s loss of exclusivity in the U.S. and the impact of China’s volume-based procurement policies.
Among the top-performing products in H1, Farxiga generated $4.0 billion in sales, followed by Tagrisso at $3.8 billion and Imfinzi at $3.5 billion.
Also read: New Hope for GVHD Patients as Rezurock Wins EU Approval
PFIZER
Q1 REVENUES
Pfizer reported first-quarter 2026 revenues of $14.5 billion, up $736 million, or 5%, compared with the same period last year.
The operational growth was mainly supported by higher sales of Padcev, Eliquis, oncology biosimilars, Nurtec, and several other products, partially offset by a decline in COVID-19–related revenues.
Also read: Johnson and Johnson approved Tecvayli plus Darzalex Faspro for 2L multiple myeloma
Q2 REVENUES/H1 REVENUES
Pfizer reported second quarter 2026 revenue of 15.0 billion dollars, reflecting 1% growth on an operational basis compared with the same period a year earlier.
For the first six months of 2026, total revenue came in at 29.5 billion dollars.
Key products contributed as follows during the quarter: Eliquis generated 4.6 billion dollars, Prevnar brought in 3.0 billion dollars, the Vyndaqel family of medicines added 3.3 billion dollars, and Ibrance recorded 2.0 billion dollars in sales.
MERCK
Q1 REVENUES
Merck reported pharmaceutical revenues of $14.3 billion, with Keytruda contributing $8.0 billion.
The growth was largely fueled by increased global demand in metastatic settings, particularly in urothelial cancer, along with strong adoption in earlier-stage treatments such as triple-negative breast cancer, cervical cancer, and renal cell carcinoma (RCC).
Q2 REVENUES:
Merck’s pharmaceutical revenue reached $14.8 billion in the second quarter, with Keytruda contributing $7.9 billion. Total first half pharmaceutical revenue came in at $29.1 billion. Across the first six months, Keytruda generated $15.8 billion, plus an additional $590 million from Keytruda Qlex. Gardasil and Gardasil 9 together added $2.2 billion in revenue.
NOVARTIS
Q1 REVENUES
Net sales totaled $13.1 billion, reflecting a decline of 1% (down 5% at constant currencies). Volume growth contributed 13 percentage points, but this was more than offset by a 14-percentage-point impact from generic competition.
Among top-performing products, Cosentyx generated $1.6 billion in revenue, while Kisqali recorded $1.5 billion.
Q2 REVENUES
Net sales increased by 1% to reach USD 14.4 billion. Growth in volumes added 18 percentage points, which was largely offset by a 14-percentage-point decline due to generic competition. Pricing pressures reduced sales by 3 percentage points, while favorable currency movements contributed an additional 2 percentage points.
For the first half of the year, net sales totaled USD 27.5 billion, reflecting a 1% increase overall and a 2% decline at constant currency. Volume expansion contributed 15 percentage points, offset by a 14-percentage-point impact from generics.
NOVO NORDISK
Q1 REVENUES:
Novo Nordisk reported net sales of DKK 96,823 million, reflecting continued momentum in its GLP-1 portfolio. The U.S. launch of the Wegovy pill on January 5, 2026, has shown rapid uptake, with weekly prescriptions surpassing 200,000 by mid-April.
Total prescriptions reached approximately 1.3 million in Q1 2026 and have exceeded 2 million since launch, positioning the product as the strongest GLP-1 launch by volume in the U.S. to date.
Q2 REVENUES/H1 REVENUES
Novo Nordisk reported second quarter sales that rose by 3% at constant exchange rates, with growth weighed down by a one time reversal of a 2.6 billion Danish krone rebate reserve linked to the 340B Drug Pricing Program in the US a year earlier.
On an adjusted basis, second quarter sales climbed by 7% at constant exchange rates, supported by continued GLP 1 volume gains across regions and more favorable rebate adjustments in the US during the quarter.
For the first half of 2026, total sales reached 27.0 billion dollars, or 175 billion Danish krone.
Wegovy injectable generated 37.7 billion krone and the oral version added 5.5 billion krone, which together amount to about 6.7 billion dollars.
Ozempic contributed 59.2 billion krone in sales, equivalent to roughly 9.1 billion dollars.
SANOFI
Q1 REVENUES
Sanofi reported first-quarter revenues of €10.5 billion. Sales from recently launched pharmaceutical products rose 49.6% to €1.2 billion, supported mainly by Ayvakit, Altuviiio, and Sarclisa.
Dupixent generated €4.2 billion in sales, reflecting a 30.8% increase and a strong opening to 2026.
Q2 REVENUES/H1 REVENUES:
Sanofi reported second-quarter revenues of $13.2 billion (€11.6 billion), contributing to first-half revenues of $25.3 billion (€22.1 billion) for H1 2026.
Dupixent remained the company’s standout product, generating $10.7 billion in sales during the first half of the year and continuing to drive overall growth
Q1: Which pharma company had the highest Q1 2026 revenue?
Johnson and Johnson reported $24.1 billion in Q1 2026 revenue (+9.9%), led by $15.4 billion from Innovative Medicines, driven by Darzalex, Carvykti, Erleada, Tremfya, and Spravato.
Q2: Which pharma company had the fastest growth in Q1 2026?
Eli Lilly posted 56% revenue growth to $19.8 billion, fueled by strong demand for Mounjaro and Zepbound, with key products generating $13.4 billion in combined sales.
Comments